Another quarter, another set of all-time highs for biotech funding – and this surfeit of capital continues raises possible concerns about its disciplined deployment.
Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace. CEO’s that I have spoken with are gravitating towards a hybrid model that requires employees to be on site for specific days but not the entire week. This is consistent with a recent PWC survey (Figure 1) suggests that only 21% of employers feel that 5 days a week in the office is required to maintain a strong culture.
By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC
I’ve been thinking a lot about growth, and for good reason: Dyne is in the midst of a significant scale-up.
By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC
In the fall of 2019, I wrote a blog called Ode to Patients. As stresses from many directions have mounted over the past 12 months, it seems that paying heed to another group now makes sense: scientists.
By Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC
If we could quantify the time and money impact of the resources invested in quarterly Board meeting preparation, I wonder if we would “invest” so much in the process?
If we knew the dollar impact and opportunity cost of CEOs’ overpreparation for Board members’ potential questions, would we shift focus to efforts that would result in more tangible value for the business?
By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC.